Cytotoxic activities of Mannich bases of chalcones and related compounds. 1998

J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
College of Pharmacy and Nutrition, Department of Chemistry, University of Saskatchewan, Saskatoon, Canada.

Various Mannich bases of chalcones and related compounds displayed significant cytotoxicity toward murine P388 and L1210 leukemia cells as well as a number of human tumor cell lines. The most promising lead molecule was 21 that had the highest activity toward L1210 and human tumor cells. In addition, 21 exerted preferential toxicity to human tumor lines compared to transformed human T-lymphocytes. Other compounds of interest were 38, with a huge differential in cytotoxicity between P388 and L1210 cells, and 42, with a high therapeutic index when cytotoxicity to P388 cells and Molt 4/C8 T-lymphocytes were compared. In general, the Mannich bases were more cytotoxic than the corresponding chalcones toward L1210 but not P388 cells. A ClusCor analysis of the data obtained from the in vitro human tumor screen revealed that the mode of action of certain groups of compounds was similar. For some groups of compounds, cytotoxicity was correlated with the sigma, pi, or molar refractivity constants in the aryl ring attached to the olefinic group. In addition, the IC50 values in all three screens correlated with the redox potentials of a number of Mannich bases. X-ray crystallography and molecular modeling of representative compounds revealed various structural features which were considered to contribute to cytotoxicity. While a representative compound 15 was stable and unreactive toward glutathione (GSH) in buffer, the Mannich bases 15, 18, and 21 reacted with GSH in the presence of the pi isozyme of glutathione S-transferase, suggesting that thiol alkylation may be one mechanism by which cytotoxicity was exerted in vitro. Representative compounds were shown to be nonmutagenic in an intrachromosomal recombination assay in yeast, devoid of antimicrobial properties and possessing anticonvulsant and neurotoxic properties. Thus Mannich bases of chalcones represent a new group of cytotoxic agents of which 21 in particular serves as an useful prototypic molecule.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D008352 Mannich Bases Ketonic amines prepared from the condensation of a ketone with formaldehyde and ammonia or a primary or secondary amine. A Mannich base can act as the equivalent of an alpha,beta unsaturated ketone in synthesis or can be reduced to form physiologically active amino alcohols. Mannich Base,Base, Mannich,Bases, Mannich
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002599 Chalcone An aromatic KETONE that forms the core molecule of CHALCONES. Benzalacetophenone,Benzylideneacetophenone,1,3-Diphenyl-2-Propen-1-One,Chalkone,1,3 Diphenyl 2 Propen 1 One
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
January 2004, European journal of medicinal chemistry,
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
November 2008, Medicinal chemistry (Shariqah (United Arab Emirates)),
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
January 2022, Medicinal chemistry (Shariqah (United Arab Emirates)),
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
February 1959, Journal of medicinal and pharmaceutical chemistry,
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
August 2003, Journal of enzyme inhibition and medicinal chemistry,
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
March 1995, Die Pharmazie,
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
November 2019, Archiv der Pharmazie,
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
January 1980, Chemotherapy,
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
March 1998, Die Pharmazie,
J R Dimmock, and N M Kandepu, and M Hetherington, and J W Quail, and U Pugazhenthi, and A M Sudom, and M Chamankhah, and P Rose, and E Pass, and T M Allen, and S Halleran, and J Szydlowski, and B Mutus, and M Tannous, and E K Manavathu, and T G Myers, and E De Clercq, and J Balzarini
April 2000, Pharmaceutica acta Helvetiae,
Copied contents to your clipboard!